Lay summary
Our project aims to combat multidrug-resistant Gram-negative bacteria by developing innovative antibiotic-nutrient conjugates. This approach significantly enhances the potency of existing antibiotics and addresses the urgent global threat of antimicrobial resistance (AMR). Pseudomonas aeruginosa, a critical pathogen in hospital infections, is our primary target due to its antibiotic resistance mechanisms. By chemically linking essential nutrients to antibiotics, we will enhance drug accumulation in bacteria, improving their effectiveness and preventing resistance.
This research fills a critical gap in antibiotic development, with no new classes for Gram-negative bacteria since the 1960s. Our strategy leverages bacterial metabolism and modern chemistry to fast-track effective antibiotics, benefiting global health and particularly aiding New Zealand's Māori and Pacific populations. Our collaboration with China will bolster research capacity, train diverse scientists, and advance global efforts against antibiotic resistance. This work will improve patient care, reduce healthcare costs, and position New Zealand as a leader in antibiotic innovation.